Authors

A. Keith Stewart, MB, ChB, Mayo Clinic

A. Keith Stewart, MB, ChB, The Mayo Clinic in Phoenix Arizona

A. Oliver Sartor, MD

Latest:

Dr Sartor on Efficacy and Safety of Lutetium Lu 177 Vipivotide Tetraxetan in Taxane-Naive mCRPC

Oliver Sartor, MD, discusses updated efficacy findings from the phase 3 PSMAfore trial of lutetium Lu 177 vipivotide tetraxetan in patients with previously treated, taxane-naive metastatic castration-resistant prostate cancer.

A. Ruth He, MD, PhD, Georgetown University Medical Center

Aakanksha Prasad Asija, MD, MPH

Latest:

When Patients Refuse Treatment for Their Cancer

Quoting statistics seemed to be a refuge to me. The objectivity of the numbers provided a hiding place and a shelter, and they helped me maintain the emotional distance that my profession demanded.

Aarati Rao, MD

Latest:

A Day In the Life of a Pediatric Oncologist

As a practicing pediatric oncologist at an academic institute, every morning begins with optimism and a quest to win the day.

Aaron C. Logan, MD, PhD, University of California San Francisco

Latest:

Dr Logan on the Integration of Obe-Cel into Relapsed/Refractory ALL Management

Aaron C. Logan, MD, PhD, discusses the FDA approval of the obe-cel in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Aaron C. Logan, MD, PhD, University of California San Francisco Medical Sciences Building

Aaron E. Katz, MD, FACS

Latest:

Dr. Katz on Redefining Risk Stratification in Prostate Cancer

Aaron E. Katz, MD, FACS, discusses redefining risk stratification for men with prostate cancer.

Aaron Gerds, MD

Aaron Gerds, MD, is an assistant professor of Medicine (Hematology and Medical Oncology) at the Cleveland Clinic Taussig Cancer Institute in Ohio.

Latest:

Dr Gerds on Notable Ongoing Clinical Trials in Myelofibrosis

Aaron T. Gerds, MD, MS, discusses clinical trials to watch in the evolving myelofibrosis research paradigm.

Aaron Goodman, MD

Latest:

Dr. Goodman on the Need for Molecular Subtyping in T-Cell Lymphomas

Aaron Goodman, MD, discusses the need for molecular subtyping in T-cell lymphomas.

Aaron Logan, MD, PhD

Aaron Logan, MD, PhD, is an associate professor of clinical medicine in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF) School of Medicine, as well as a member of the UCSF Helen Diller Family Comprehensive Cancer Center

Latest:

Obe-Cel Data Are Poised to Refine and Expand the ALL Treatment Paradigm: With Aaron Logan, MD, PhD; and Bijal Shah, MD, MS

Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm and how the use of this agent might expand going forward.

Aaron S. Mansfield, MD

Latest:

Dr. Mansfield Discusses Ongoing Trials With Chemoimmunotherapy in Mesothelioma

Aaron S. Mansfield, MD, discusses ongoing trials with chemoimmunotherapy in mesothelioma.

Aaron S. Mansfield MD, Tobias Peikert, MD

Latest:

Potential Applications of Immune Checkpoint Blockade for Mesothelioma

Malignant pleural mesothelioma (MPM) is an inexorably progressive and almost universally fatal malignancy.

Aarti S. Bhardwaj, MD

Latest:

Common Adverse Effects of Anti-HER2 Therapies and Practical Management Recommendations

The benefits of trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) have all been well studied, but each drug also has its own set of complications and toxicities.

Aashini Master, DO

Latest:

Dr. Master on the Mediterranean Diet in Relation to Breast Cancer Risk

Aashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the Mediterranean diet in relation to breast cancer risk.

Abdenour Nabid, MD

Latest:

Dr. Nabid on a Shorter Duration of ADT in Prostate Cancer

Abdenour Nabid, MD, from the Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of ADT to 36 in men with high-risk, localized prostate cancer.

Abdulraheem Yacoub, MD

Latest:

Exploring the Future of MF Treatment

The panel closes their discussion by highlighting novel agents in the treatment of myeloproliferative neoplasms to look out for.

Abhinav Deol, MD

Latest:

Dr Deol on Potential Avenues for CAR T-Cell Therapy Research in Multiple Myeloma

Abhinav Deol, MD, discusses ongoing and potential research avenues for improving the use of CAR T-cell therapy in multiple myeloma.

Abigail L. Stockham, MD

Latest:

The Role of Radiation in the Management of Brain Metastases

In this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.